Analytical Data
-
基因名
CDK9
- Application
-
别名
CDK9；CDC2L4；TAK；Cyclin-dependent kinase 9
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P50750
-
表达区间
1-372aa
-
氨基酸序列
MAKQYDSVEC PFCDEVSKYE KLAKIGQGTF GEVFKARHRK TGQKVALKKV LMENEKEGFP ITALREIKIL QLLKHENVVN LIEICRTKAS PYNRCKGSIY LVFDFCEHDL AGLLSNVLVK FTLSEIKRVM QMLLNGLYYI HRNKILHRDM KAANVLITRD GVLKLADFGL ARAFSLAKNS QPNRYTNRVV TLWYRPPELL LGERDYGPPI DLWGAGCIMA EMWTRSPIMQ GNTEQHQLAL ISQLCGSITP EVWPNVDNYE LYEKLELVKG QKRKVKDRLK AYVRDPYALD LIDKLLVLDP AQRIDSDDAL NHDFFWSDPM PSDLKGMLST HLTSMFEYLA PPRRKGSQIT QQSTNQSRNP ATTNQTEFER VF
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CDK9, or Cyclin-Dependent Kinase 9, is a pivotal enzyme that plays a critical role in the regulation of transcription and cell cycle progression. It is a key member of the CDK family, primarily associated with RNA polymerase II phosphorylation, which is essential for the transcriptional elongation process. Dysregulation of CDK9 has been implicated in various pathological conditions, including cancer, where aberrant expression or activity contributes to uncontrolled cellular proliferation. Research into CDK9 has gained momentum due to its potential as a therapeutic target; various small molecule inhibitors are being explored for their ability to selectively inhibit CDK9 activity. Recombination and expression of CDK9 in heterologous systems have been crucial for studying its biochemical properties and interactions with regulatory proteins, enabling a deeper understanding of its role in transcriptional control. Investigating the structural and functional characteristics of CDK9 through recombinant protein techniques enhances our knowledge of its enzymatic mechanisms and aids in the development of novel inhibitors that could serve as effective cancer treatments. As a result, the study of CDK9 recombinant proteins continues to represent a significant area of research with promising implications for targeted therapies in oncology and other related diseases.
